Cequa (cyclosporine 900 microgram/mL), is a TGA approved, novel aqueous, nanomicellar ophthalmic cyclosporine solution, for treatment of moderate-to-severe keratoconjunctivitis sicca (dry eye), where prior use of artificial tears has not been sufficient.1,2
Cequa, a calcineurin inhibitor immunosuppressant, has novel nanomicellar technology which improves the formulation’s bioavailability and allows for a more than 10-fold increase in the aqueous solubility of cyclosporine.3
Two clinical studies, OTX-101-2014-0014 and OTX-101-2016-001,3 demonstrated that Cequa yields clinically and statistically significant improvements in tear production and ocular surface integrity over 84 days.3
Contact: Sun Pharma Medical Information (AUS) 1800 726 229
- Therapeutic Goods Administration (TGA). Summary for ARTG entry – CEQUA ciclosporin 900 microgram/mL eye drops ampoule. [cited 2019; Available from: https://www.ebs.tga.gov.au/servlet/xmlmillr6?dbid=ebs/PublicHTML/pdfStore.nsf&docid=0C8BC94E164C7646CA258500003C9B8E&agid=(PrintDetailsPublic)&actionid=1.
- CEQUA® Product Information. 2020 Feb, 2020]; Available from: Sun Pharma by calling 1800 726 229.
- Goldberg, D.F., et al., A Phase 3, Randomized, Double-Masked Study of OTX-101 Ophthalmic Solution 0.09% in the Treatment of Dry Eye Disease. Ophthalmology, 2019. 126(9): p. 1230-1237.
- Tauber, J., et al., A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease. Clinical ophthalmology (Auckland, N.Z.), 2018. 12: p. 1921-1929.